Does cytochrome P450 liver isoenzyme induction increase the risk of liver toxicity after paracetamol overdose?

Open Access Emergency Medicine

Volumn 3, Issue , 2011, Pages 69-76

  Kalsi, Sarbjeet S ^a   Wood, David M ^a,b   Waring, W Stephen ^c   Dargan, Paul I ^a,b  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c YORK TEACHING HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Hepatotoxicity; Isoenzymes; Overdose; Paracetamol

Indexed keywords

CARBAMAZEPINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 ISOENZYME; EFAVIRENZ; ISONIAZID; N ACETYL 1,4 BENZOQUINONE IMINE; NEVIRAPINE; PARACETAMOL; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; RIFABUTIN; RIFAMPICIN;

DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG GLUCURONIDATION; DRUG INTOXICATION; DRUG OVERDOSE; ENZYME INDUCTION; ENZYME INHIBITION; FIRST PASS EFFECT; HIGH RISK PATIENT; HUMAN; HYPERICUM PERFORATUM; LIVER TOXICITY; NONHUMAN; REVIEW; RISK ASSESSMENT; RISK FACTOR; TOXIC HEPATITIS;

EID: 84861448581     PISSN: None     EISSN: 11791500     Source Type: Journal    
DOI: 10.2147/OAEM.S24962     Document Type: Review

References (77)

1. Davidson DG, Eastham WN. Acute liver necrosis following overdose of paracetamol. Br Med J. 1966;2(5512):497-499.
2. Thomson JS, Prescott LF. Liver damage and impaired glucose tolerance after paracetamol overdosage. Br Med J. 1966;2(5512):506-507.
3. Gow PJ, Smallwood RA, Angus PW. Paracetamol overdose in a liver transplantation centre: an 8-year experience. J Gastroenterol Hepatol. 1999;14(8):817-821.
4. Brandsaeter B, Hockerstedt K, Friman S, et al. Fulminant hepatic failure: outcome after listing for highly urgent liver transplantation-12 years experience in the nordic countries. Liver Transpl. 2002;8(11):1055-1062.
5. Tessier G, Villeneuve E, Villeneuve JP. Etiology and outcome of acute liver failure: experience from a liver transplantation centre in Montreal. Can J Gastroenterol. 2002;16(10):672-676.
6. Larson AM, Polson J, Fontana RJ, et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology. 2005;42(6):1364-1372.
7. Bernal W, Cross TJ, Auzinger G, et al. Outcome after wait-listing for emergency liver transplantation in acute liver failure: a single centre experience. J Hepatol. 2009;50(2):306-313.
8. Clemmesen JO, Ott P, Dalhoff KP, Astrup LB, Tage-Jensen U, Poulsen HE. Recommendations for treatment of paracetamol poisoning Danish Medical Society, Study of the Liver. Ugeskr Laeger. 1996;158(48):6892-6895.
9. Wallace CI, Dargan PI, Jones AL. Paracetamol overdose: an evidence based flowchart to guide management. Emerg Med J. 2002;19(3): 202-205.
10. Brok J, Buckley N, Gluud C. Interventions for paracetamol (acetaminophen) overdose. Cochrane Database Syst Rev. 2006;2: CD003328.
11. Wolf SJ, Heard K, Sloan EP, Jagoda AS; American College of Emergency Physicians.Clinical policy: critical issues in the management of patients presenting to the emergency department with acetaminophen overdose. Ann Emerg Med. 2007;50(3):292-313.
12. Daly FF, Fountain JS, Murray L, Graudins A, Buckley NA. Guidelines for the management of paracetamol poisoning in Australia and New Zealand - explanation and elaboration. A consensus statement from clinical toxicologists consulting to the Australasian poisons information centres. Med J Aust. 2008;188(5):296-301.
13. NPIS. TOXBASE: The primary clinical toxicological database of the National Poisons Information Service. National Poisons Information Service; cited April 8, 2011; Available from: http://www.toxbase.org/Poisons-Index-A-Z/P-Products/Paracetamol------------/.
14. Vale JA, Proudfoot AT. Paracetamol (acetaminophen) poisoning. Lancet. 1995;346(8974):547-552.
15. Waring WS, Robinson OD, Stephen AF, Dow MA, Pettie JM. Does the patient history predict hepatotoxicity after acute paracetamol overdose? QJM. 2008;101(2):121-125.
16. Buckley NA, Whyte IM, O'Connell DL, Dawson AH. Activated charcoal reduces the need for N-acetylcysteine treatment after acetaminophen (paracetamol) overdose. J Toxicol Clin Toxicol. 1999;37(6):753-757.
17. Mitchell JR, Jollow DJ, Potter WZ, Davis DC, Gillette JR, Brodie BB. Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism. J Pharmacol Exp Ther. 1973;187(1):185-194.
18. Potter WZ, Davis DC, Mitchell JR, Jollow DJ, Gillette JR, Brodie BB. Acetaminophen-induced hepatic necrosis. 3. Cytochrome P-450-mediated covalent binding in vitro. J Pharmacol Exp Ther. 1973;187(1):203-210.
19. Corcoran GB, Mitchell JR, Vaishnav YN, Horning EC. Evidence that acetaminophen and N-hydroxyacetaminophen form a common arylating intermediate, N-acetyl-p-benzoquinoneimine. Mol Pharmacol. 1980;18(3):536-542.
20. Dahlin DC, Nelson SD. Synthesis, decomposition kinetics, and preliminary toxicological studies of pure N-acetyl-p-benzoquinone imine, a proposed toxic metabolite of acetaminophen. J Med Chem. 1982;25(8):885-886.
21. Mitchell JR, Jollow DJ, Potter WZ, Gillette JR, Brodie BB. Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathione. J Pharmacol Exp Ther. 1973;187(1):211-217.
22. Jollow DJ, Thorgeirsson SS, Potter WZ, Hashimoto M, Mitchell JR. Acetaminophen-induced hepatic necrosis. VI. Metabolic disposition of toxic and nontoxic doses of acetaminophen. Pharmacology. 1974;12(4-5):251-271.
23. Mitchell JR, Thorgeirsson SS, Potter WZ, Jollow DJ, Keiser H. Acetaminophen-induced hepatic injury: protective role of glutathione in man and rationale for therapy. Clin Pharmacol Ther. 1974;16(4):676-684.
24. Potter WZ, Thorgeirsson SS, Jollow DJ, Mitchell JR. Acetaminopheninduced hepatic necrosis. V. Correlation of hepatic necrosis, covalent binding and glutathione depletion in hamsters. Pharmacology. 1974;12(3):129-143.
25. Prescott LF, Roscoe P, Wright N, Brown SS. Plasma-paracetamol half-life and hepatic necrosis in patients with paracetamol overdosage. Lancet. 1971;1(7698):519-522.
26. Rumack BH, Matthew H. Acetaminophen poisoning and toxicity. Pediatrics. 1975;55(6):871-876.
27. Lee WM. Review article: drug-induced hepatotoxicity. Aliment Pharmacol Ther. 1993;7(5):477-485.
28. Ostapowicz G, Fontana RJ, Schiodt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002;137(12):947-954.
29. Hamlyn AN, James OF, Lesna M, Roberts SH, Watson AJ, Douglas AP. Proceedings: Liver function tests and histology in survivors of acute paracetamol (acetaminophen) poisoning. Gut. 1975;16(10):838.
30. James O, Lesna M, Roberts SH, et al. Liver damage after paracetamol overdose. Comparison of liver-function tests, fasting serum bile acids, and liver histology. Lancet. 1975;2(7935):579-581.
31. Prescott LF. Paracetamol overdosage. Pharmacological considerations and clinical management. Drugs. 1983;25(3):290-314.
32. O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology. 1989;97(2):439-445.
33. Harrison PM, O'Grady JG, Keays RT, Alexander GJ, Williams R. Serial prothrombin time as prognostic indicator in paracetamol induced fulminant hepatic failure. BMJ. 1990;301(6758):964-966.
34. Dahlin DC, Miwa GT, Lu AY, Nelson SD. N-acetyl-p-benzoquinone imine: a cytochrome P-450-mediated oxidation product of acetaminophen. Proc Natl Acad Sci U S A. 1984;81(5):1327-1331.
35. Chen W, Koenigs LL, Thompson SJ, et al. Oxidation of acetaminophen to its toxic quinone imine and nontoxic catechol metabolites by baculovirus-expressed and purified human cytochromes P450 2E1 and 2A6. Chem Res Toxicol. 1998;11(4):295-301.
36. Manyike PT, Kharasch ED, Kalhorn TF, Slattery JT. Contribution of CYP2E1 and CYP3A to acetaminophen reactive metabolite formation. Clin Pharmacol Ther. 2000;67(3):275-282.
37. Zaher H, Buters JT, Ward JM, et al. Protection against acetaminophen toxicity in CYP1A2 and CYP2E1 double-null mice. Toxicol Appl Pharmacol. 1998;152(1):193-199.
38. Raucy JL, Lasker JM, Lieber CS, Black M. Acetaminophen activation by human liver cytochromes P450IIE1 and P450IA2. Arch Biochem Biophys. 1989;271(2):270-283.
39. Thummel KE, Lee CA, Kunze KL, Nelson SD, Slattery JT. Oxidation of acetaminophen to N-acetyl-p-aminobenzoquinone imine by human CYP3A4. Biochem Pharmacol. 1993;45(8):1563-1569.
40. Snawder JE, Roe AL, Benson RW, Roberts DW. Loss of CYP2E1 and CYP1A2 activity as a function of acetaminophen dose: relation to toxicity. Biochem Biophys Res Commun. 1994;203(1):532-539.
41. Sarich T, Kalhorn T, Magee S, et al. The effect of omeprazole pretreatment on acetaminophen metabolism in rapid and slow metabolizers of S-mephenytoin. Clin Pharmacol Ther. 1997;62(1):21-28.
42. Dong H, Haining RL, Thummel KE, Rettie AE, Nelson SD. Involvement of human cytochrome P450 2D6 in the bioactivation of acetaminophen. Drug Metab Dispos. 2000;28(12):1397-1400.
43. Laine JE, Auriola S, Pasanen M, Juvonen RO. Acetaminophen bioactivation by human cytochrome P450 enzymes and animal microsomes. Xenobiotica. 2009;39(1):11-21.
44. Hazai E, Vereczkey L, Monostory K. Reduction of toxic metabolite formation of acetaminophen. Biochem Biophys Res Commun. 2002;291(4):1089-1094.
45. De Gregori M, Allegri M, De Gregori S, et al. How and why to screen for CYP2D6 interindividual variability in patients under pharmacological treatments. Curr Drug Metab. 2010;11(3):276-282.
46. Zhao L, Pickering G. Paracetamol metabolism and related genetic differences. Drug Metab Rev. 2011;43(1):41-52.
47. Cheng J, Ma X, Krausz KW, Idle JR, Gonzalez FJ. Rifampicin-activated human pregnane X receptor and CYP3A4 induction enhance acetaminophen-induced toxicity. Drug Metab Dispos. 2009;37(8): 1611-1621.
48. Tomlinson B, Young RP, Ng MC, Anderson PJ, Kay R, Critchley JA. Selective liver enzyme induction by carbamazepine and phenytoin in Chinese epileptics. Eur J Clin Pharmacol. 1996;50(5):411-415.
49. Wolf KK, Wood SG, Allard JL, et al. Role of CYP3A and CYP2E1 in alcohol-mediated increases in acetaminophen hepatotoxicity: comparison of wild-type and Cyp2e1(-/-) mice. Drug Metab Dispos. 2007;35(7):1223-1231.
50. Kostrubsky SE, Sinclair JF, Strom SC, et al. Phenobarbital and phenytoin increased acetaminophen hepatotoxicity due to inhibition of UDP-glucuronosyltransferases in cultured human hepatocytes. Toxicol Sci. 2005;87(1):146-155.
51. Mutlib AE, Goosen TC, Bauman JN, Williams JA, Kulkarni S,Kostrubsky S. Kinetics of acetaminophen glucuronidation by UDPglucuronosyltransferases 1A1, 1A6, 1A9 and 2B15. Potential implications in acetaminophen-induced hepatotoxicity. Chem Res Toxicol. 2006;19(5):701-709.
52. Hariparsad N, Nallani SC, Sane RS, Buckley DJ, Buckley AR, Desai PB. Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital. J Clin Pharmacol. 2004;44(11):1273-1281.
53. Zhang JG, Ho T, Callendrello AL, Crespi CL, Stresser DM. A multiendpoint evaluation of cytochrome P450 1A2, 2B6 and 3A4 induction response in human hepatocyte cultures after treatment with beta-naphthoflavone, phenobarbital and rifampicin. Drug Metab Lett. 2010;4(4):185-194.
54. Poulsen HE, Lerche A, Pedersen NT. Phenobarbital induction does not potentiate hepatotoxicity but accelerates liver cell necrosis from acetaminophen overdose in the rat. Pharmacology. 1985;30(2):100-108.
55. Blouin RA, Dickson P, McNamara PJ, Cibull M, McClain C. Phenobarbital induction and acetaminophen hepatotoxicity: resistance in the obese Zucker rodent. J Pharmacol Exp Ther. 1987;243(2): 565-570.
56. Douidar SM, Ahmed AE. A novel mechanism for the enhancement of acetaminophen hepatotoxicity by phenobarbital. J Pharmacol Exp Ther. 1987;240(2):578-583.
57. Minton NA, Henry JA, Frankel RJ. Fatal paracetamol poisoning in an epileptic. Hum Toxicol. 1988;7(1):33-34.
58. Pirotte JH. Apparent potentiation of hepatotoxicity from small doses of acetaminophen by phenobarbital. Ann Intern Med. 1984;101(3):403.
59. Bray GP, Harrison PM, O'Grady JG, Tredger JM, Williams R. Longterm anticonvulsant therapy worsens outcome in paracetamol-induced fulminant hepatic failure. Hum Exp Toxicol. 1992;11(4):265-270.
60. Edwards RJ, Price RJ, Watts PS, et al. Induction of cytochrome P450 enzymes in cultured precision-cut human liver slices. Drug Metab Dispos. 2003;31(3):282-288.
61. Luo G, Cunningham M, Kim S, et al. CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos. 2002;30(7):795-804.
62. Lystbaek BB, Norregaard P. A case of paracetamol retard poisoning with fatal outcome. Ugeskr Laeger. 1995;157(7):899-900.
63. Prescott LF, Critchley JA, Balali-Mood M, Pentland B. Effects of microsomal enzyme induction on paracetamol metabolism in man. Br J Clin Pharmacol. 1981;12(2):149-153.
64. Suchin SM, Wolf DC, Lee Y, et al. Potentiation of acetaminophen hepatotoxicity by phenytoin, leading to liver transplantation. Dig Dis Sci. 2005;50(10):1836-1838.
65. Cook MD, Williams SR, Clark RF. Phenytoin-potentiated hepatotoxicity following acetaminophen overdose? A closer look. Dig Dis Sci. 2007;52(1):208-209.
66. McClements BM, Hyland M, Callender ME, Blair TL. Management of paracetamol poisoning complicated by enzyme induction due to alcohol or drugs. Lancet. 1990;335(8704):1526.
67. Bogan J, Smith H. The relation between primidone and phenobarbitone blood levels. J Pharm Pharmacol. 1968;20(1):64-67.
68. Perucca E, Richens A. Paracetamol disposition in normal subjects and in patients treated with antiepileptic drugs. Br J Clin Pharmacol. 1979;7(2):201-206.
69. Trapnell CB, Jamis-Dow C, Klecker RW, Collins JM. Metabolism of rifabutin and its 25-desacetyl metabolite, LM565, by human liver microsomes and recombinant human cytochrome P-450 3A4: relevance to clinical interaction with fluconazole. Antimicrob Agents Chemother. 1997;41(5):924-926.
70. Lamson MJ, Sabo JP, MacGregor TR, et al. Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers. Biopharm Drug Dispos. 1999;20(6):285-291.
71. Gurley BJ, Gardner SF, Hubbard MA, et al. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther. 2002;72(3):276-287.
72. Markowitz JS, Donovan JL, DeVane CL, et al. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA. 2003;290(11):1500-1504.
73. Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, Hall SD. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther. 2001;70(4):317-326.
74. Wenk M, Todesco L, Krahenbuhl S. Effect of St John's wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xanthine oxidase in healthy males and females. Br J Clin Pharmacol. 2004;57(4):495-499.
75. Chien JY, Thummel KE, Slattery JT. Pharmacokinetic consequences of induction of CYP2E1 by ligand stabilization. Drug Metab Dispos. 1997;25(10):1165-1175.
76. Zand R, Nelson SD, Slattery JT, et al. Inhibition and induction of cytochrome P4502E1-catalyzed oxidation by isoniazid in humans. Clin Pharmacol Ther. 1993;54(2):142-149.
77. Chien JY, Peter RM, Nolan CM, et al. Influence of polymorphic N-acetyltransferase phenotype on the inhibition and induction of acetaminophen bioactivation with long-term isoniazid. Clin Pharmacol Ther. 1997;61(1):24-34.